Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells (2024)

Glöckner, H. J., Martinenaite, E., Landkildehus Lisle, T., Grauslund, J., Ahmad, S., Met, Ö., Thor Straten, P. (2024). Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells. OncoImmunology, 13(1), [2318053]. https://doi.org/10.1080/2162402X.2024.2318053

Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells. / Glöckner, Hannah Jorinde; Martinenaite, Evelina; Landkildehus Lisle, Thomas; Grauslund, Jacob; Ahmad, Shamaila; Met, Özcan; Thor Straten, Per; Hald Andersen, Mads.

In: OncoImmunology, Vol. 13, No. 1, 2318053, 2024.

Research output: Contribution to journal › Journal article › Research › peer-review

Glöckner, HJ, Martinenaite, E, Landkildehus Lisle, T, Grauslund, J, Ahmad, S, Met, Ö, Thor Straten, P 2024, 'Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells', OncoImmunology, vol. 13, no. 1, 2318053. https://doi.org/10.1080/2162402X.2024.2318053

Glöckner HJ, Martinenaite E, Landkildehus Lisle T, Grauslund J, Ahmad S, Met Ö et al. Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells. OncoImmunology. 2024;13(1). 2318053. https://doi.org/10.1080/2162402X.2024.2318053

Glöckner, Hannah Jorinde ; Martinenaite, Evelina ; Landkildehus Lisle, Thomas ; Grauslund, Jacob ; Ahmad, Shamaila ; Met, Özcan ; Thor Straten, Per ; Hald Andersen, Mads. / Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells. In: OncoImmunology. 2024 ; Vol. 13, No. 1.

@article{1d880ea5942e459d80168f31b667d540,

title = "Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells",

abstract = "Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and cancer patients. However, while the function of anti-regulatory Arg1-specific CD4+ T cells has been characterized, our knowledge of CD8+ Arg1-specific T cells is only scarce. In the current study, we describe the immune-modulatory capabilities of CD8+ Arg1-specific T cells. We generated CD8+ Arg1-specific T cell clones to target Arg1-expressing myeloid cells. Our results demonstrate that these T cells recognize both malignant and nonmalignant regulatory myeloid cells in an Arg1-expression-dependent manner. Notably, Arg1-specific CD8+ T cells possess cytolytic effector capabilities. Immune modulatory vaccines (IMVs) represent a novel treatment modality for cancer. The activation of Arg1-specific CD8+ T cells through Arg1-based IMVs can contribute to the modulatory effects of this treatment strategy.",

keywords = "anti-regulatory T cells, Arginase-1, immune modulatory vaccines, myeloid cells, tumor microenvironment",

author = "Gl{\"o}ckner, {Hannah Jorinde} and Evelina Martinenaite and {Landkildehus Lisle}, Thomas and Jacob Grauslund and Shamaila Ahmad and {\"O}zcan Met and {Thor Straten}, Per and {Hald Andersen}, Mads",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

doi = "10.1080/2162402X.2024.2318053",

language = "English",

volume = "13",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells

AU - Glöckner, Hannah Jorinde

AU - Martinenaite, Evelina

AU - Landkildehus Lisle, Thomas

AU - Grauslund, Jacob

AU - Ahmad, Shamaila

AU - Met, Özcan

AU - Thor Straten, Per

AU - Hald Andersen, Mads

N1 - Publisher Copyright:© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2024

Y1 - 2024

N2 - Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and cancer patients. However, while the function of anti-regulatory Arg1-specific CD4+ T cells has been characterized, our knowledge of CD8+ Arg1-specific T cells is only scarce. In the current study, we describe the immune-modulatory capabilities of CD8+ Arg1-specific T cells. We generated CD8+ Arg1-specific T cell clones to target Arg1-expressing myeloid cells. Our results demonstrate that these T cells recognize both malignant and nonmalignant regulatory myeloid cells in an Arg1-expression-dependent manner. Notably, Arg1-specific CD8+ T cells possess cytolytic effector capabilities. Immune modulatory vaccines (IMVs) represent a novel treatment modality for cancer. The activation of Arg1-specific CD8+ T cells through Arg1-based IMVs can contribute to the modulatory effects of this treatment strategy.

AB - Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have been observed in both healthy individuals and cancer patients. However, while the function of anti-regulatory Arg1-specific CD4+ T cells has been characterized, our knowledge of CD8+ Arg1-specific T cells is only scarce. In the current study, we describe the immune-modulatory capabilities of CD8+ Arg1-specific T cells. We generated CD8+ Arg1-specific T cell clones to target Arg1-expressing myeloid cells. Our results demonstrate that these T cells recognize both malignant and nonmalignant regulatory myeloid cells in an Arg1-expression-dependent manner. Notably, Arg1-specific CD8+ T cells possess cytolytic effector capabilities. Immune modulatory vaccines (IMVs) represent a novel treatment modality for cancer. The activation of Arg1-specific CD8+ T cells through Arg1-based IMVs can contribute to the modulatory effects of this treatment strategy.

KW - anti-regulatory T cells

KW - Arginase-1

KW - immune modulatory vaccines

KW - myeloid cells

KW - tumor microenvironment

U2 - 10.1080/2162402X.2024.2318053

DO - 10.1080/2162402X.2024.2318053

M3 - Journal article

C2 - 38404966

AN - SCOPUS:85185495776

VL - 13

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - 2318053

ER -